Completed
Cyclosporine vs. Infliximab for Acute Severe UC Treatment Failure, %
Class Central Classrooms beta
YouTube videos curated by Class Central.
Classroom Contents
Advances in Inflammatory Bowel Disease
Automatically move to the next video in the Classroom when playback concludes
- 1 Intro
- 2 Changing Geographic Distribution of IBD
- 3 Main Susceptibility Genes for Crohn's Disease
- 4 Microbial Diversity in Crohn's Disease
- 5 Management of Mild to Moderate UC
- 6 Estimate of Efficacy of AZA for Treatment Success in UC Patients: Meta-Analysis
- 7 Infliximab for UC: ACT 1 and ACT 2 Clinical Remission
- 8 ACT1/2 Trials: Survival Free of Colectomy
- 9 Cyclosporine vs. Infliximab for Acute Severe UC Treatment Failure, %
- 10 Management of Crohn's Disease
- 11 Construct of Biologic Agents Used in Crohn's Disease
- 12 Induction of Clinical Remission at Week 4 In Crohn's Disease: Certolizumab, Adalimumab, Infliximab
- 13 Natalizumab (Anti-Alpha 4 Integrin) Therapy for Crohn's Disease
- 14 Baseline Factors Associated with Time to Surgery: Crohn's, Olmsted County, 1970-2004
- 15 Advances in IBD Natural History: Predictors of More Severe Disease
- 16 CT Enterography Healing: Equivalent to Mucosal Healing at Endoscopy?
- 17 TPMT Activity in 407 New Zealand Patients
- 18 Meta-Analysis: Association Between 6-TGN Levels and Clinical Remission
- 19 Effect of Trough Serum Infliximab Concentrations on Clinical Outcome at 52 Weeks
- 20 What Factors influence the Pharmacokinetics of TNF Antagonists?
- 21 Active Monitoring of Anti-TNF Levels May Ensure Durability of Response
- 22 Effect of Concomitant Azathioprine or Methotrexate on Anti-drug Antibodies
